Clinical trial
Gefitinib in the Treatment of the First Relapse of Prostate Cancer Beyond…
NCT00241475 · AstraZeneca, Industry · Completed
Key facts
| NCT number | NCT00241475 |
|---|---|
| Title | Gefitinib in the Treatment of the First Relapse of Prostate Cancer Beyond Prostatectomy or Radiotherapy |
| Official title | An Open Label, Non-Comparative, Phase II Study of ZD1839 (Iressa) as First-Line Treatment in Subjects With Relapsed Prostate Cancer Following Radical Prostatectomy or Radiotherapy |
| Lead sponsor | AstraZeneca, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Prostate Cancer |
| Intervention type | Drug |
| Interventions | Gefitinib |
| Enrollment | 30 |
| Start date | Dec 1, 2003 |
| Completion | Oct 1, 2005 |
| First posted | Oct 19, 2005 |
| Last update posted | Apr 23, 2009 |
| Countries | Finland |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: